Cohort Study for the Assessment of Long-term Impact of COVID-19 Among Moderate and Severe COVID-19 Patients in Brazil
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Hospital Moinhos de Vento
- Enrollment
- 650
- Locations
- 24
- Primary Endpoint
- One-year utility score of health related quality of life
- Status
- Active, Not Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The present prospective cohort study aims to assess factors associated with of one-year health-related quality of life and physical, cognitive and mental health outcomes among adult survivors of hospitalization for COVID-19. Adult patients requiring hospitalization due to COVID-19 disease will be followed through structured and centralized telephone interviews performed at 3, 6, 9 and 12 months after enrollment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age ≥18 years;
- •Symptomatic COVID-19 disease within the last 14 days;
- •Positive polymerase chain reaction (PCR) test for SARS-CoV-2 within the last 14 days;
- •Need of hospitalization (duration ≥ 48 hours).
Exclusion Criteria
- •Severe comorbidity with life expectancy less than 3 months;
- •Death during hospitalization;
- •Absence of telephone contact;
- •Absence of proxy for patients with communication difficulties;
- •Refusal or withdrawal of agreement to participate;
- •Previous enrollment in the study.
Outcomes
Primary Outcomes
One-year utility score of health related quality of life
Time Frame: The outcome will be assessed 12 months after enrollment.
The outcome will be assessed using the Brazilian version of the Euroqol-5D-3L (EQ-5D3L) questionnaire.
Secondary Outcomes
- Instrumental Activities of Daily Living(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
- Utility score of health related quality of life at 3, 6, and 9 months(The outcome will be assessed at 3, 6, and 9 months after enrollment.)
- Incidence of major cardiovascular events(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
- Prevalence of anxiety and depression symptoms(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
- Incidence of rehospitalizations(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
- Prevalence of prolonged COVID-19 symptoms(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
- Prevalence of posttraumatic stress disorder symptoms(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
- Incidence of return to work or study(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
- Incidence of all-cause mortality(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
- Prevalence of cognitive dysfunction(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
- Incidence of new symptomatic COVID-19 infection(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)
- Physical functional status(The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.)